Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial
Table 3
Pre- and post-treatment characteristics of the 485 subjects who developed biochemical (Phoenix) failure before clinical failure according to the most predictive post-biochemical failure risk category (BFRC) stratification scheme.
Post-biochemical failure risk category
Low
Intermediate
High
()
()
()
Gleason score
2–6
117 (47%)
36 (30%)
23 (19%)
7
105 (43%)
53 (44%)
54 (45%)
8–10
24 (10%)
31 (26%)
42 (35%)
T stage
T2b
73 (30%)
23 (19%)
16 (13%)
T2c
87 (35%)
33 (28%)
36 (30%)
T3,4
86 (35%)
64 (53%)
67 (56%)
PSA (g/L)
<10
45 (18%)
24 (20%)
20 (17%)
≥10 and <20
102 (41%)
38 (32%)
24 (20%)
≥20
99 (40%)
58 (48%)
75 (63%)
Risk group*
Intermediate
45 (18%)
10 (8%)
4 (3%)
High
201 (82%)
110 (92%)
115 (97%)
Primary treatment
0 months AST
107 (44%)
45 (38%)
40 (34%)
3 months AST
75 (30%)
35 (29%)
45 (38%)
6 months AST
64 (26%)
40 (33%)
34 (28%)
Age at BF (years)
Median (range)
74 (54–89)
69 (54–88)
69 (44–81)
PSADT (months)
Median (IQR)
13.2 (9.4–19.8)
5.3 (4.3–6.4)
3.0 (1.9–3.8)
TTBF (years)
Median (IQR)
4.6 (3.4–7.3)
2.2 (1.5–2.7)
0.8 (0.5–1.4)
STI
No STI
121 (49%)
13 (11%)
8 (7%)
STI without distant progression
89 (36%)
61 (51%)
47 (39%)
STI with distant progression
36 (15%)
46 (38%)
64 (54%)
: number of subjects; PSA: prostate-specific antigen; AST: androgen suppression therapy; PSADT: PSA doubling time; TTBF: time from biochemical (Phoenix) failure; STI: secondary therapeutic intervention; IQR: interquartile range.
*D’Amico et al. risk classification.
